ADRENACLICK Drug Patent Profile

When do Adrenaclick patents expire, and what generic alternatives are available?

Adrenaclick is a drug marketed by Impax and is included in one NDA.

The generic ingredient in ADRENACLICK is epinephrine. There is one drug master file entry for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adrenaclick

A generic version of ADRENACLICK was approved as epinephrine by BPI LABS on July 29^th, 2014.

Summary for ADRENACLICK

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	2
Patent Applications:	4,124
Drug Prices:	Drug price information for ADRENACLICK
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ADRENACLICK
DailyMed Link:	ADRENACLICK at DailyMed

See drug prices for ADRENACLICK

Recent Clinical Trials for ADRENACLICK

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Arthroplasty Foundation, Inc.	Phase 4
University of Louisville	Phase 4
NYU Langone Health	N/A

See all ADRENACLICK clinical trials

US Patents and Regulatory Information for ADRENACLICK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Impax	ADRENACLICK	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	020800-003	Nov 25, 2009	BX	RX	Yes	Yes
Impax	ADRENACLICK	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	020800-004	Nov 25, 2009	BX	RX	Yes	Yes

Expired US Patents for ADRENACLICK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Impax	ADRENACLICK	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	020800-003	Nov 25, 2009	10,166,334
Impax	ADRENACLICK	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	020800-004	Nov 25, 2009	10,166,334
Impax	ADRENACLICK	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	020800-003	Nov 25, 2009	5,665,071
Impax	ADRENACLICK	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	020800-004	Nov 25, 2009	10,166,344
Impax	ADRENACLICK	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	020800-003	Nov 25, 2009	10,166,344

International Patents for ADRENACLICK

See the table below for patents covering ADRENACLICK around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2005314174	Method and apparatus for delivering epinephrine
Australia	2005314401	Medicine injection devices and methods
Brazil	PI0518415	aparelho formando um dispositivo de injeÇço de medicamento, e, mÉtodos para acionar uma agulha de seringa atÉ uma profundidade de penetraÇço selecionada, e para injetar medicamento de uma seringa e armazenar a seringa apàs injeÇço do medicamento
Brazil	PI0518460	mÉtodo para tratar emergÊncia alÉrgica em um paciente, dispositivo de distribuiÇço de droga contendo uma soluÇço de epinefrina, e, kit para tratar uma emergÊncia alÉrgia'
Canada	2585707	PROCEDE ET DISPOSITIF DE DELIVRANCE D'EPINEPHRINE (METHOD AND APPARATUS FOR DELIVERING EPINEPHRINE)

Supplementary Protection Certificates for ADRENACLICK

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3678649	LUC00378	Luxembourg		PRODUCT NAME: COMBINAISON D'EPINEPHRINE ET DE DODECYLMALTOSIDE, SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20250211
3678649	2025C/508	Belgium		PRODUCT NAME: COMBINATIE VAN EPINEPHRINE EN DODECYLMALTOSIDE, IN ALLE VORMEN BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20240823

ADRENACLICK market dynamics and financial trajectory (2026): exclusivity window, competitive pressure, and revenue risk profile

Last updated: July 24, 2026

Adrenaclick (epinephrine) is an FDA-approved, prescription-only auto-injector in the adrenaline emergency treatment space (anaphylaxis). Market dynamics are driven by (1) payer coverage of branded epinephrine auto-injectors, (2) formulary tiering of competing devices, (3) US patent and exclusivity timing for branded entries, and (4) inventory behavior ahead of shelf-life and device procurement cycles. A revenue trajectory for ADRENACLICK depends on whether payers shift volume to lower-cost competitors and on whether device manufacturers gain contracting position via price, rebates, and distribution.

What matters most for financial forecasting is the interaction between exclusivity/expiration milestones and the competitive device ramp of rival branded and authorized generics (where applicable), plus ongoing demand elasticity from health systems, schools, and emergency care providers.

---

What is ADRENACLICK’s current US market structure and who competes?

Adrenaclick competes in the US epinephrine auto-injector market, where branded offerings have historically split demand across payers and institutional buyers. The core buying groups are:

• Retail pharmacies for individual patients and caregivers.
• Institutional channels that stock emergency kits (schools, workplaces, long-term care).
• Pharmacy benefit managers that set formulary placement and rebate structures.

Competitor set by product class

Common competitive products in the same therapeutic and device class include (non-exhaustive):

• EpiPen (and authorized follow-on landscape where applicable)
• Auvi-Q
• Symjepi
• Generic and “authorized generic” auto-injector programs (where FDA approvals and manufacturer contracts support supply)

How competition shows up in financials

Device products with similar clinical effect compete on:

• WAC-to-NADAC discounting and PBM rebates
• Formulary placement (preferred vs non-preferred tiers)
• Contract awards to institutional distributors
• Avoidance of stockouts and reliability perceptions

---

How do payer and formulary dynamics drive ADRENACLICK revenue?

Featured snippet answer: ADRENACLICK revenue is most sensitive to formulary tiering and rebate intensity, because epinephrine auto-injectors are high-frequency “must-have” purchases but still subject to payer switching when a lower-cost preferred option is available.

Formulary placement mechanics

• Preferred tier placement usually requires rebate or contracting economics.
• Non-preferred placement shifts demand from retail to cash-pay or limited insurance coverage scenarios.
• Institutional procurement often locks in supplier status for budget cycles, with periodic re-bids.

Switching and substitution

• Substitution can occur when therapeutically equivalent devices are available and payer policies allow interchange.
• The presence of a lower-cost preferred device often compresses branded net pricing.

Net price and volume linkage

Financial outcomes tend to hinge on two variables:

• Net price per unit after rebates
• Units sold driven by patient adoption and institutional stock-up cycles

---

What does the exclusivity and patent landscape mean for ADRENACLICK’s financial trajectory?

Featured snippet answer: The near-to-mid-term financial trajectory depends on whether ADRENACLICK is protected mainly by formulation and device patents versus method-of-use claims, and on when those protections expire or are weakened by FDA-referenced follow-on approvals.

Key drivers

• Patent expirations: determine the window for generic or device-equivalent competition.
• Delays via patent litigation: can push launch dates.
• Exclusivity: can act as a backstop even when certain patents lapse.

Practical revenue implication

• If patent and exclusivity barriers prevent competitive device entry, ADRENACLICK sustains higher net pricing.
• If barriers fall, volume and net price both face downward pressure.

---

When does ADRENACLICK lose market exclusivity? What is the expiration timeline?

Featured snippet answer: A concrete “lose exclusivity” date requires a specific Orange Book record with listed expiration dates for ADRENACLICK, plus any pediatric exclusivity or other regulatory exclusivity extensions. Without that Orange Book listing captured in this dataset, an exact expiration timetable cannot be produced.

---

What patents protect ADRENACLICK and how strong is the estate?

Featured snippet answer: Patent strength for ADRENACLICK is measured by claim breadth across device components, formulation (epinephrine concentration/stability), and manufacturing/packaging attributes that are needed for FDA approval and can be designed around.

What to evaluate in an ADRENACLICK patent estate

• Independent claim coverage for device + drug-product combination.
• Whether claims are method-of-use versus composition/device.
• Whether key claims are near-expiration or already litigated/invalidated.
• Whether claim language is narrow enough for design-around via alternative injector design.

Commercially relevant “weak points”

Revenue risk increases if the estate:

• Is heavily dependent on a single narrow formulation or stability claim
• Faces prior art exposure that supports invalidity arguments
• Has limited coverage for the specific manufacturing and packaging steps required for supply

---

What patent litigation affects ADRENACLICK and what outcomes drive launch timing?

Featured snippet answer: For branded auto-injectors, launch timing typically tracks settlement-triggered “carve-out” dates or court-ordered injunctions. A precise litigation impact requires listing of Paragraph IV or equivalent challenges and any settlement agreements tied to ADRENACLICK’s Orange Book patents. Those records are not provided in the current input, so a dated litigation timeline cannot be stated.

---

What is the Orange Book status of ADRENACLICK (listed patents and exclusivities)?

Featured snippet answer: Orange Book status is the single best forward-looking indicator for branded epinephrine auto-injector erosion. However, an itemized Orange Book table (patent numbers, expiration dates, exclusivity codes, and dosage form mappings) cannot be produced here without the underlying Orange Book data.

---

What formulation, device, or manufacturing IP barriers exist for generic or follow-on entry?

Featured snippet answer: ADRENACLICK’s risk of follow-on encroachment is tied to how tightly IP connects epinephrine stability and container-closure performance with specific injector mechanics.

Common barriers in epinephrine auto-injectors

• Stability and preservative system constraints
• Device spring force, needle deployment sequence, and dwell time
• Container-closure compatibility affecting potency
• Manufacturing controls to meet USP-like performance expectations

Business implication

Even if a patent expires, practical launch can lag if:

• Qualified suppliers are scarce
• Device validation cycles are long
• Post-approval changes trigger new comparability packages or stability commitments

---

How does ADRENACLICK compare with EpiPen, Auvi-Q, and other epinephrine auto-injectors on commercialization dynamics?

Featured snippet answer: In the US, epinephrine auto-injector revenue usually reflects “channel lock-in” more than differential clinical outcomes, because all products target the same acute emergency endpoint.

Comparison dimensions that move units and net pricing

• Patient and caregiver preference (training simplicity, sound cues, needle angle)
• Institutional familiarity and stocking practices
• Payer coverage policies by state and PBM
• Bundle pricing and rebate competitiveness

Forecast impact

If a competitor becomes preferred on major formularies, ADRENACLICK’s unit share tends to fall, which then forces net price erosion across remaining volume.

---

What commercial adoption drivers support or weaken ADRENACLICK demand?

Demand support factors

• Prescribing inertia in primary care and allergy clinics.
• School/workplace stock policies, especially after policy adoption in certain states.
• Prescription renewals driven by patient age and device shelf-life cycles.

Demand headwinds

• Device cost sensitivity by payers.
• Switching to lower-cost preferred options.
• Inventory optimization by institutions to reduce wastage.

---

What is the revenue and earnings trajectory for ADRENACLICK (US)?

A dated financial trajectory (revenue numbers, unit sales, or guidance) cannot be produced from the provided input because specific company financial disclosures and sales figures for ADRENACLICK are not included.

What can be concluded from market mechanics:

• Near-term revenue is primarily a function of net pricing under rebate/formulary contracts and the ability to maintain distribution.
• Over time, revenue risk increases when exclusivity and patent barriers weaken and alternative products become preferred.

---

What generic entry risks exist for ADRENACLICK under FDA pathways?

Featured snippet answer: Generic or follow-on entry risk exists when:

• Orange Book-listed patents expire or are weakened,
• FDA can approve a follow-on product under an appropriate pathway, and
• Manufacturing and device performance packages clear. Specific entry date risk requires the Orange Book patent list and any associated challenge history, which is not provided here.

---

How does international market presence change the financial profile of ADRENACLICK?

Featured snippet answer: International revenue is typically less predictable unless there is parallel regulatory approval and pricing flexibility across markets. Auto-injector reimbursement and tender systems can materially alter uptake even if clinical performance is equivalent.

No jurisdictional sales trajectory can be quantified without access to country approvals, reimbursement decisions, and company segment reporting.

---

Key Takeaways

• ADRENACLICK’s financial trajectory is driven less by clinical differentiation and more by payer formulary tiering, rebate economics, and institutional contracting cycles.
• Competitive pressure in epinephrine auto-injectors tends to compress net pricing first and then unit share when preferred alternatives gain access.
• A precise “exclusivity loss” timeline, Orange Book status table, and patent-litigation schedule require Orange Book and litigation records that are not included in the current input.
• Net revenue outlook over the exclusivity window depends on how durable ADRENACLICK’s patent/device barriers are and how quickly the market can switch to lower-cost devices after those barriers fall.
• Forecasting accuracy improves by modeling unit volumes against preferred-tier status and by tracking inventory and shelf-life driven reorder cycles in institutional channels.

---

FAQs

1. What drives net pricing for epinephrine auto-injectors like ADRENACLICK in PBM contracts?
2. How do shelf-life and institutional procurement cycles affect epinephrine auto-injector unit volumes?
3. What patent claim types most often determine whether a device follow-on can launch after exclusivity?
4. How does FDA approval timing for device performance packages influence launch readiness even after patents expire?
5. What indicators show when a branded auto-injector is shifting from preferred to non-preferred formulary status?

---

References

1. FDA Orange Book. “Drug Products (Orange Book)”. U.S. Food and Drug Administration.
2. FDA. “Approval Pathways for Generic Drugs and Related Guidance”. U.S. Food and Drug Administration.